See every side of every news story
Published loading...Updated

Continuous Manufacturing Helps mAb Firms Innovate and Cut Costs

Continuous manufacturing makes monoclonal antibody production faster, cheaper, and greener, say researchers, who predict that industry adoption of the approach will accelerate in response to competitive pressure. Most therapeutic antibodies are made as batches, using discrete processes that run for a defined period. This, in large part, reflects the success of early drugs like Enbrel, Humira, and Avastin, which established fed-batch processes as…

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

GEN - Genetic Engineering and Biotechnology News… broke the news in on Wednesday, July 9, 2025.
Sources are mostly out of (0)